Our TYK2 franchise is led by ESK-001, a TYK2 inhibitor currently in clinical development for moderate to severe plaque psoriasis and systemic lupus erythematosus (SLE).

This highly selective inhibitor has the potential to effectively treat multiple immune-mediated indications.

We are also developing A-005, a CNS-penetrating, allosteric TYK2 inhibitor for neuro-inflammatory diseases such as multiple sclerosis (MS).

Beyond TYK2, we have several earlier-stage discovery assets, comprised of targets identified by our precision data analytics platform, for the potential treatment of immune-mediated indications. 

About ESK-001

An oral, next-generation TYK2 inhibitor

Our lead candidate ESK-001 is an investigational oral, highly selective, next-generation tyrosine kinase 2 (TYK2) inhibitor with a differentiated pharmacological profile compared with other available or investigational molecules with similar mechanism of action. ESK-001 is being evaluated in Phase 3 clinical trials for the treatment of moderate to severe plaque psoriasis and a Phase 2b clinical trial for the treatment of systemic lupus erythematosus (SLE).

Learn More

About A-005

A potential first-in-class CNS-penetrant allosteric TYK2 inhibitor

A-005 is designed to achieve maximal TYK2 inhibition and to cross the blood brain barrier for localized treatment both within the CNS and in the periphery, supporting its potential across multiple TYK2-mediated indications. TYK2 is a protein that plays a role in mediating signaling responses to key proinflammatory cytokines, including interleukin (IL)-23 and type 1 interferon.

A-005 completed a Phase 1 clinical trial in healthy participants and is expected to enter a Phase 2 clinical trial in patients with multiple sclerosis in the second half of 2025.

Additional Programs / Discovery Efforts

Beyond TYK2, we have several earlier-stage discovery assets comprised of targets identified by our precision data analytics platform for the potential treatment of immune-mediated indications.
 

clinical Programs